Eveia Medical, Inc. is developing two  proprietary testing platforms that will enable healthcare providers and life science researchers to better manage patients, diagnose disease and develop targeted therapeutics and diagnostics.

The Rapid Testing (Point-of-Care) technology enables cost-effective management of many of the most common disease states, and completely eliminates the need for any instrumentation and reagents.  Single use devices in development include tests for anemia (Hb), coagulation (Coumadin therapy), c-Reactive Protein (CRP), HbA1c and numerous other applications in clinical medicine.

The HIA (Homogeneous ImmunoAssay) analyzer system approaches the sensitivity of mass spectrometry and is capable of rapid and reliable measurements, with enhanced specificity, of virtually any biomarker for clinical research, pathology laboratories, Physician-Office–Laboratories (POL) and research laboratories.